Search results
Merck Wins US Approval for Pneumonia Vaccine to Rival Pfizer’s
Bloomberg· 1 day agoMerck & Co. won US approval for a pneumococcal vaccine that threatens to unseat one of Pfizer Inc.’s...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 6 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 6 days agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Pfizer Inc. (NYSE:PFE) Stake Boosted by Wellington Management Group LLP
ETF DAILY NEWS· 2 days agoWellington Management Group LLP lifted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 4.9% during the 4th quarter, according to its most recent disclosure ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 5 days agoPfizer disclosed on May 7 that a child participating in another...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open
Barrons.com· 5 days agoThe drug company Pfizer said a gene therapy it is testing failed to improve motor function in boys...
Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading...
Benzinga· 1 day agoThe state of Kansas has reportedly filed a lawsuit against pharmaceutical giant Pfizer, Inc. PFE, accusing the company of violating consumer protection laws related to its ...
Merck’s vaccine approval poses threat to one of Pfizer’s top-selling products
Market Watch· 1 day ago“We’ll provide protection that’s broader than anything that’s out there,” Art Hirt, senior vice...
7,403 Shares in Pfizer Inc. (NYSE:PFE) Bought by Gerber LLC
ETF DAILY NEWS· 2 days agoGerber LLC bought a new position in Pfizer Inc. (NYSE:PFE – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 7,403 shares of the biopharmaceutical ...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 5 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...